MATINAS BIOPHARMA HOLDINGS, INC. Deferred Revenue
MATINAS BIOPHARMA HOLDINGS, INC. (MTNB) had Deferred Revenue of $29.94 thousand as of 2017-12-31, per its 10-K filed 2019-04-01.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2019-04-01
- 2017-12-31: Deferred Revenue, Current $29.94K.
- 2017-09-30: Deferred Revenue, Current $74.84K.
- 2017-06-30: Deferred Revenue, Current $119.75K.
- 2017-03-31: Deferred Revenue, Current $164.66K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2017-12-31 | $29.94K 10-K · filed 2019-04-01 |
| 2017-09-30 | $74.84K 10-Q · filed 2017-11-14 |
| 2017-06-30 | $119.75K 10-Q · filed 2017-08-08 |
| 2017-03-31 | $164.66K 10-Q · filed 2017-05-15 |
| 2016-12-31 | $0.00 10-Q · filed 2017-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| Nexentis Technologies Inc. (NXTS) | $0.002B |